Tofacitinib for juvenile idiopathic arthritis - Authors' reply
Lancet
.
2022 May 14;399(10338):1866.
doi: 10.1016/S0140-6736(22)00837-6.
Authors
Nicolino Ruperto
1
,
Hermine I Brunner
2
,
Holly B Posner
3
,
Irina Lazariciu
3
,
Alberto Martini
4
,
Daniel J Lovell
2
;
Paediatric Rheumatology International Trials Organisation and Pediatric Rheumatology Collaborative Study Group
Affiliations
1
IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, 16147 Genoa, Italy. Electronic address: nicolaruperto@gaslini.org.
2
College of Medicine, University of Cincinnati, and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
3
Pfizer, New York, NY, USA.
4
Università degli Studi di Genova, Genoa, Italy.
PMID:
35569465
DOI:
10.1016/S0140-6736(22)00837-6
No abstract available
Publication types
Letter
Comment
MeSH terms
Arthritis, Juvenile* / drug therapy
Humans
Piperidines / therapeutic use
Pyrimidines / therapeutic use
Substances
Piperidines
Pyrimidines
tofacitinib